1 |
Health insurance Review & Assesment service of Korea. statistical data. 2010
|
2 |
Harbert JC. Radioiodine therapy of differentiated thyroid carcinoma. Nuclear Medical therapy. New York Thiem Medical Publishers p.36-90, 1987
|
3 |
ICRP: Recommendations of the international commission on Radiological Protection,ICRP Publication 26, Pergamon Press, Oxford, New York, 1977
|
4 |
Goldsmith SJ, Malblant JC, Nuclear Oncology. Philadelphia Lippincott Williams & Wilkin, pp.195-220. 2001
|
5 |
Lubin, E. Definitive improment in the approach to the treated patient as a radioactive source. J Nucl Med, Vol 43, No. 3, pp 364-5, Mar 2002
|
6 |
Siegel JA, Marcus CS, Sparks RB. Calculating the absorbed dose from radioactive patients: the line source versus point source model. J Nucl Med Vol. 43, No. 9, pp 124-4, 2002
|
7 |
Gui-Won Lee. Minimized Radiation dose of patients receiving high dose radioiodine therapy. JKRS, Vol. 30. No. 4, pp 435-442, 2007
|
8 |
C.G Kim, Are Medical personnel safe from radiation exposure from patient receiving radioiodine ablation therapy. Nucl Med Mol Imaging Vol. 43. No. 4, Aug 2009
|
9 |
B.S Chang, S.H Kim, J.K Ahn., Radiation dose rate PET-scan patients injection with F-18-FDG, NPSM, Vol. 62, No. 12, pp. 1345-1350, December 2010.
|
10 |
M. Elschot et al, The influence of self-absorption on pet/ct shielding requirements, J Med. Phys Vol. 37, No 6, pp. 2999-3007, June 2010.
DOI
ScienceOn
|
11 |
Korea Atomic Energy Research Institute, Certificate for Detector Calibration, 2013
|
12 |
ICRP Publication 94, Release of patients after therapy with unsealed radionuclides, pp 53-58, Ann. ICRP 34 (2), 200
|